ArticleBMC research notes2025
SQSTM1/p62 as a prognostic indicator in pancancer and nasopharyngeal carcinoma.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study evaluated SQSTM1/p62 expression patterns and its prognostic value across multiple cancers, with a focus on nasopharyngeal carcinoma (NPC). RESULTS DESCRIPTION: SQSTM1/p62 showed significantly higher mRNA and protein levels in tumors versus normal tissues across cancer types. High SQSTM1/p62 expression correlated with poorer OS and DSS in multiple cancers. Among 86 NPC patients (median follow-up 46.8 months), high SQSTM1/p62 expression (69.8% vs CNP 45% in controls, P = 0.036) independently predicted reduced DSS (HR = 4.51, 95% CI: 1.40-14.52). The unadjusted and multivariable-adjusted models consistently revealed a stable relationship between SQSTM1/p62 expression and patient prognosis. No significant interaction was observed between SQSTM1/p62 expression and age, TNM stage, or treatment methods (induction chemotherapy, concurrent chemoradiotherapy, adjuvant chemotherapy). In summary, elevated SQSTM1/p62 expression correlates with poor clinical outcomes in pancancer analyses and serves as an independent prognostic factor for NPC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.